Mexico Antirheumatic Drugs market was valued at US$2,389.634 million in 2019. Rising Mexican population suffering from arthritis is the major driver of the antirheumatic drugs market in Mexico. Arthritis does not affect only the elderly population, lifestyle, and work influence also results in the development of arthritis in adults. As such, the growing working population with a sitting job is also leading to the rising prevalence of arthritis in Mexico, thereby fuelling the antirheumatic drugs market growth in the country. Another major driver of the Mexican antirheumatic drugs market is the growing medical tourism industry in the country supported by the OTC (over-the-counter) availability of cheaper prescription drugs in the country. Rising healthcare costs and wait time in the U.S. and Canada is encouraging people to turn to Mexico for purchasing cheaper drugs and medicines. According to the U.S. government estimates, nearly 1 million people in California alone visit Mexico annually for health care services, including to buy prescription drugs. The presence of larger independent pharmacy chains and discount drug stores in Mexico as well rising sales of OTC drugs through the non-pharmacy sector of the market is attracting a number of U.S. companies to set up joint development deals with Mexican retailers to boost the sales of OTC drugs, thus positively impacting the growth of antirheumatic drugs market.
Mexico Antirheumatic Drugs market has been segmented based on the type of disease, type of molecule, and sales channel. By type of disease, the market has been segmented as osteoarthritis,rheumatoid arthritis, gout, lupus, and others. By type of molecule, Mexico Antirheumatic Drugs market has been classified into pharmaceuticals and biopharmaceuticals. The market segmentation has also been done by sales channel as prescription and over-the-counter (OTC).